Home / News / Stock market / Barclays says buy Novo Nordisk stock 'into this critically important catalyst'

Stock market

Barclays says buy Novo Nordisk stock 'into this critically important catalyst'

Investing | Sat, Nov 23 2024 01:45 AM AEDT

stock

Image Source:

Investing.com -- Barclays analysts are bullish on Novo Nordisk (NYSE:NVO) stock ahead of the December release of pivotal clinical trial data for its next-generation obesity treatment, CagriSema.

The results of the REDEFINE-1 Phase 3 trial could, according to Barclays (LON:BARC), "redefine the obesity landscape" and provide a much-needed boost to the company's stock, which has faced a turbulent second half of 2024.

They explained that CagriSema combines two active ingredients: cagrilintide, an amylin receptor analog, and semaglutide, a GLP-1 receptor analog. This dual mechanism of action aims to create a synergistic effect on weight loss.

Novo Nordisk has set a minimum target of 25% weight loss in the trial, which would make CagriSema the most effective weight-loss drug commercially available.

Barclays is optimistic, stating, "We believe that Novo will hit this bar of 25% weight loss."

The Danish pharmaceutical giant's stock has suffered a 27% decline since June, underperforming the European pharmaceutical index (SXDP) by 24%.

Factors contributing to this slump include "slight misses" in second- and third-quarter results, concerns over Wegovy's prescription growth in the U.S., and broader sector rotation following the U.S. presidential election.

Despite these challenges, Barclays maintains confidence in Novo Nordisk's long-term growth prospects, emphasizing that success with CagriSema could reverse the recent slide in the share price.

Barclays projects a potential 14% upside to its current net present value estimates for Novo Nordisk if the trial achieves its weight-loss target, even accounting for expected gastrointestinal side effects.

The analysts conclude, "We reiterate our Overweight rating into this critically important catalyst."

This article first appeared in Investing.com

More For You

Stock Market

Gulfport Energy upgraded at KeyBanc on Trump tailwinds

Investing | Sat, Nov 23 2024 06:15 AM AEDT

stock

Investing.com -- KeyBanc Capital Markets raised its price target on Gu...

Stock Market

Temu parent PDD extends decline after JP Morgan downgrades stock

Investing | Sat, Nov 23 2024 03:19 AM AEDT

stock

Investing.com -- U.S.-listed shares of Temu parent PDD Holdings Inc DR...

Stock Market

Roblox stock added to analyst current favorites list at Raymond James

Investing | Sat, Nov 23 2024 02:41 AM AEDT

stock

Investing.com -- Raymond (NS:RYMD) James analysts added Roblox Corp (N...